Drug Profile
CardiALLO cell therapy - BioCardia
Alternative Names: BCDA 03; BCDA 04; BCDA-03-CardiALLO cell therapy; CardiALLO; Neurokinin 1 receptor positive mesenchymal stem cell therapy - BioCardia; NK1R+ MSCLatest Information Update: 13 Oct 2023
Price :
$50
*
At a glance
- Originator BioCardia
- Developer BioCardia; University of Miami
- Class Cell therapies; Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Heart failure
- Phase II Ischaemic heart disorders; Left ventricular dysfunction; Myocardial infarction
- Preclinical SARS-CoV-2 acute respiratory disease
Most Recent Events
- 08 Sep 2023 BioCardia initiates a phase I/II trial for Heart failure(Intracoronary) in the USA (NCT05925608)
- 09 Aug 2023 BioCardia plans a phase I/II (BCDA-03) trial for heart failure with reduced ejection fraction (HFrEF) in the third quarter of 2023
- 05 Jul 2023 BioCardia plans a phase I/II trial for Heart failure (Intracoronary), in July 2023 (NCT05925608)